As of 2026-09-19, the EV/EBITDA ratio of Y-mAbs Therapeutics, Inc (YMAB) is -15.86. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. YMAB's latest enterprise value is 328.95 mil USD. YMAB's TTM EBITDA according to its financial statements is -20.75 mil USD. Dividing these 2 quantities gives us the above YMAB EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 16.6x - 17.9x | 17.0x |
| Forward P/E multiples | 19.4x - 23.4x | 20.9x |
| Fair Price | (7.48) - (6.79) | (7.28) |
| Upside | -186.8% - -178.9% | -184.6% |
| Date | EV/EBITDA |